A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2015
Price : $35 *
At a glance
- Drugs Dovitinib (Primary) ; Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 12 Jan 2015 Planned initiation date changed from 1 Nov 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.